Technology transfer has always been a critical step in bringing products from development to commercial manufacturing—but in 2026, regulatory expectations are becoming more defined and more closely scrutinized.
The U.S. Food and Drug Administration is placing increased emphasis on how organizations execute and document tech transfer activities, particularly as companies expand manufacturing networks, utilize contract manufacturers, and scale complex therapies.
As supply chains evolve and timelines accelerate, tech transfer is no longer just an operational milestone—it is a key compliance risk area.
Why Tech Transfer Is a Regulatory Focus
Tech transfer involves moving product knowledge, processes, and analytical methods from one site or organization to another. This may include transferring from R&D to manufacturing, between internal sites, or to a contract manufacturing organization (CMO/CDMO).
From a regulatory perspective, this process must ensure that product quality, safety, and performance remain consistent regardless of where or how the product is manufactured.
Failures in tech transfer can lead to variability, deviations, or even product quality issues—making it a critical point of regulatory oversight.
What FDA Inspectors Are Looking For
In 2026, FDA inspections are increasingly focused on how well tech transfer activities are planned, executed, and controlled.
Key areas of focus include:
- Process understanding and documentation, ensuring that critical process parameters and quality attributes are clearly defined
- Comparability between sites, demonstrating that transferred processes produce equivalent results
- Validation and qualification activities, including equipment, methods, and processes
- Knowledge transfer and training, ensuring receiving teams fully understand the process
- Change control and risk management, documenting all changes and associated risks
These elements must be clearly documented and traceable throughout the transfer lifecycle.
Common Challenges in Tech Transfer
Despite its importance, tech transfer often presents challenges—especially under tight timelines or during rapid scale-up.
Common issues include incomplete documentation, gaps in process understanding, insufficient communication between sending and receiving sites, and misalignment between quality systems.
When these gaps occur, they can result in deviations, failed batches, or delays in commercialization.
In many cases, the root issue is not technical—it is organizational.
The Impact of Global Manufacturing Networks
As companies increasingly rely on global manufacturing networks and external partners, tech transfer complexity continues to grow.
Working with CMOs and CDMOs introduces additional layers of oversight, requiring clear quality agreements, defined responsibilities, and strong communication channels.
Organizations must ensure that all parties are aligned on expectations, processes, and compliance requirements.
Without this alignment, even well-designed transfers can face execution challenges.
Building a Structured Tech Transfer Framework
To meet evolving regulatory expectations, organizations must approach tech transfer as a structured, cross-functional process.
This includes early planning, detailed documentation, defined roles and responsibilities, and ongoing monitoring of transfer activities.
Risk-based approaches can help prioritize critical elements, while strong governance ensures consistency across projects.
Most importantly, organizations must treat tech transfer as an extension of their quality system—not a standalone activity.
How EMMA International Supports Tech Transfer and Compliance
At EMMA International, we support organizations in designing and executing successful tech transfer strategies that align with regulatory expectations.
Our teams provide expertise in process development, validation, quality systems, regulatory strategy, and operational execution to ensure seamless transitions from development to manufacturing.
As regulatory expectations continue to evolve, organizations that invest in structured, well-controlled tech transfer processes will be best positioned to scale efficiently while maintaining compliance.
References
U.S. Food and Drug Administration. Process Validation: General Principles and Practices.
International Council for Harmonisation (ICH). Q8, Q9, and Q10 Guidelines.
International Society for Pharmaceutical Engineering (ISPE). Technology Transfer Guidance
